4 Healthcare Stock Stories for the Well-Being of Investors

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Eli Lilly and Company (NYSE:LLY): Current price $52.88

Lilly and its wholly owned subsidiary Avid Radiopharmaceuticals, said late Tuesday that Amyvid (Florbetapir F 18 Injection) has received European Commission marketing authorization as a diagnostic radiopharmaceutical that is indicated for Positron Emission Tomography imaging of beta-amyloid neuritic plaque density in the brains of adult patients suffering from cognitive impairment who are being studied for Alzheimer’s disease and other causes of cognitive impairment. In is noted that Amyvid should be used in conjunction with a clinical evaluation.

Picture 13

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business